Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07588152 · ClinicalTrials.gov registry record · Phase 4
Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
A Phase 4 study, sponsored by Indiana University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT07588152 is a Phase 4 study that is actively recruiting participants, run by Indiana University. The registered enrollment target is 50 participants.
The verdict
NCT07588152, a Phase 4 study, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.
Interventions
- DRUG Netarsudil Ophthalmic Solution (Rhopressa)
- OTHER Artificial Tears (AT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-06-05 |
| Est. Completion | 2028-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07588152
The ClinicalTrials.gov registry entry for NCT07588152 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Netarsudil Ophthalmic Solution (Rhopressa) is the first listed.
NCT07588152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07588152 about?
NCT07588152 is a clinical study titled "Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension". This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, ant...
What is the current status of trial NCT07588152?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2026-06-05. Estimated completion is 2028-06.
What interventions are being tested in trial NCT07588152?
The interventions under investigation include: Netarsudil Ophthalmic Solution (Rhopressa) (DRUG), Artificial Tears (AT) (OTHER).
Who is sponsoring clinical trial NCT07588152?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.